Could a pill after surgery keep early lung cancer from coming back?

NCT ID NCT07686185

First seen Jul 07, 2026 · Last updated Jul 08, 2026 · Updated 1 time

Summary

This study looks at how well third-generation EGFR-targeted drugs work as follow-up treatment after surgery for people with early-stage non-small cell lung cancer that has certain high-risk features. Researchers will observe about 500 patients in China who have EGFR mutations and have had their stage IA tumor removed. The goal is to see if taking these drugs for three years helps prevent the cancer from returning and to track any side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
third-generation EGFR-TKIs (osimertinib, aumolertinib, furmonertinib)
What this could lead to
If successful, this could show that targeted therapy after surgery helps prevent early-stage lung cancer from returning in high-risk patients.
What could go wrong
This is an observational study, not a controlled trial, so results may be less conclusive. The therapy may not benefit all patients and could cause side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADJUVANT THERAPY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • The First Affiliated Hospital of Guangxi Medical University

    Nanning, Guangxi, 530021, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.